Drugs / FE203799
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03417765 | Sep 2018 → Mar 2019 | Hodgkins lymphoma, non-Hodgkin lymphoma | GlyPharma Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03415594 | May 2018 → Nov 2019 | short bowel syndrome | GlyPharma Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT03408132 | May 2018 → Oct 2019 | short bowel syndrome | GlyPharma Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FE 203799 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03417765 ↗ |
| Action | Activate | “Glucagon-like peptide 2 receptor agonist” CHEMBL4563522 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4563522 ↗ |
| Route | Subcutaneous | “FE203799 5 mg subcutaneous once weekly” NCT03408132 ↗ |
| Target | GLP2R | “Glucagon-like peptide 2 receptor agonist” CHEMBL4563522 ↗ |